scholarly article | Q13442814 |
P356 | DOI | 10.1093/JAC/DKM372 |
P698 | PubMed publication ID | 17913723 |
P50 | author | Eva Poveda | Q24934124 |
Vicente Soriano | Q55277832 | ||
Juan González-Lahoz | Q117269375 | ||
Angélica Corral | Q117269384 | ||
P2093 | author name string | Carmen de Mendoza | |
Carolina Garrido | |||
Julio Cobo | |||
P433 | issue | 6 | |
P407 | language of work or name | English | Q1860 |
P304 | page(s) | 1409-1410 | |
P577 | publication date | 2007-10-03 | |
P1433 | published in | Journal of Antimicrobial Chemotherapy | Q6294770 |
P1476 | title | Prevalence of etravirine (TMC-125) resistance mutations in HIV-infected patients with prior experience of non-nucleoside reverse transcriptase inhibitors | |
P478 | volume | 60 |
Q36020992 | Antiretroviral drugs: critical issues and recent advances |
Q36276790 | Antiviral drug resistance and the need for development of new HIV-1 reverse transcriptase inhibitors |
Q37252113 | Canadian consensus guidelines for the optimal use of etravirine in the treatment of HIV-infected adults |
Q33902540 | Constrained patterns of covariation and clustering of HIV-1 non-nucleoside reverse transcriptase inhibitor resistance mutations |
Q33973857 | Etravirine (TMC-125): The evidence for its place in the treatment of HIV-1 infection |
Q37228725 | Etravirine for the treatment of HIV infection. |
Q37405054 | Etravirine: a second-generation NNRTI for treatment-experienced adults with resistant HIV-1 infection |
Q37359827 | Evolution of drug resistance after virological failure of a first-line highly active antiretroviral therapy regimen in Uganda. |
Q33558937 | Factors associated with virological response to etravirine in nonnucleoside reverse transcriptase inhibitor-experienced HIV-1-infected patients |
Q35567828 | Impact of antiretroviral therapy on lipid metabolism of human immunodeficiency virus-infected patients: Old and new drugs |
Q39599947 | Impact of the N348I mutation in HIV-1 reverse transcriptase on nonnucleoside reverse transcriptase inhibitor resistance in non-subtype B HIV-1. |
Q37306123 | Pharmacologic aspects of new antiretroviral drugs |
Q83197990 | Pharmacologic aspects of new antiretroviral drugs |
Q37288671 | The Need for Development of New HIV-1 Reverse Transcriptase and Integrase Inhibitors in the Aftermath of Antiviral Drug Resistance |
Search more.